Recommended diagnostic criteria for paraneoplastic neurological syndromes

F Graus, J Y Delattre, J C Antoine, J Dalmau, B Giometto, W Grisold, J Honnorat, P Sillevis Smitt, Ch Vedeler, J J G M Verschuuren, A Vincent, R Voltz, for the Paraneoplastic Neurological Syndrome Euronetwork

Background: Paraneoplastic neurological syndromes (PNS) are defined by the presence of cancer and exclusion of other known causes of the neurological symptoms, but this criterion does not separate “true” PNS from neurological syndromes that are coincidental with a cancer.

Objective: To provide more rigorous diagnostic criteria for PNS.

Methods: An international panel of neurologists interested in PNS identified those defined as “classical” in previous studies. The panel reviewed the existing diagnostic criteria and recommended new criteria for those in whom no clinical consensus was reached in the past. The panel reviewed all reported onconeural antibodies and established the conditions to identify those that would be labelled as “well characterised”. The antibody information was obtained from published work and from unpublished data from the different laboratories involved in the study.

Results: The panel suggest two levels of evidence to define a neurological syndrome as paraneoplastic: “definite” and “possible”. Each level can be reached combining a set of criteria based on the presence or absence of cancer and the definitions of “classical” syndrome and “well characterised” onconeural antibody.

Conclusions: The proposed criteria should help clinicians in the classification of their patients and the prospective and retrospective analysis of PNS cases.

Paraneoplastic neurological syndromes (PNS) were initially defined as neurological syndromes of unknown cause that often associate with cancer (table 1). This broad definition leaves open the possibility of considering as PNS any neurological syndrome that merely coincides with the presence of a cancer without pathogenetic relation between the two disorders. In the last two decades, the discovery that many PNS are associated with antibodies against neural antigens expressed by the tumour (onconeural antibodies), has suggested that some PNS are immune mediated. The detection of onconeural antibodies has been extremely useful in indicating the presence of a tumour and defining a given neurological syndrome as paraneoplastic. However, PNS may occur without onconeural antibodies, and the antibodies can occur without a neurological syndrome; therefore, their presence should not be the only condition for defining a neurological syndrome as paraneoplastic.

As all PNS are rare, it is important to be able to pool data from different centres to define new onconeural antibodies and new syndromes. Besides, there is a lack of uniform criteria to diagnose some PNS. For these reasons, internationally accepted diagnostic criteria of PNS would be advantageous. In November 2002 an international panel of neurologists interested in PNS identified those defined as “classical” in previous studies. The panel decided not to include in this review the following syndromes: myasthenia gravis, paraproteinemic neuropathies, and paraneoplastic retinopathies because they are usually discussed in other clinical forums. The panel reviewed the existing diagnostic criteria of the different classical syndromes and recommended new criteria for those in whom no clinical consensus was reached in the past. Then, the panel reviewed all reported onconeural antibodies and established the conditions to identify those that would be labelled as well characterised. The antibody information was obtained from published work and from unpublished data from the different laboratories involved in the study. Anti-voltage gated calcium channel (VGCC) antibodies were not included in the list of onconeural antibodies, despite sharing some common features, because in the case of Lambert-Eaton myasthenic syndrome (LEMS) the antibody does not predict the presence of cancer.

On the basis of their discussion, the panel concluded that the diagnostic criteria of a neurological syndrome as paraneoplastic should be based on the presence or absence of cancer and the definitions of classical syndrome and well characterised onconeural antibody.

METHODS
The panel first considered the different syndromes known as paraneoplastic (table 1) and identified those defined as classical in previous studies. The panel decided not to include in this review the following syndromes: myasthenia gravis, paraproteinemic neuropathies, and paraneoplastic retinopathies because they are usually discussed in other clinical forums. The panel reviewed the existing diagnostic criteria of the different classical syndromes and recommended new criteria for those in whom no clinical consensus was reached in the past. Then, the panel reviewed all reported onconeural antibodies and established the conditions to identify those that would be labelled as well characterised. The antibody information was obtained from published work and from unpublished data from the different laboratories involved in the study. Anti-voltage gated calcium channel (VGCC) antibodies were not included in the list of onconeural antibodies, despite sharing some common features, because in the case of Lambert-Eaton myasthenic syndrome (LEMS) the antibody does not predict the presence of cancer.

On the basis of their discussion, the panel concluded that the diagnostic criteria of a neurological syndrome as paraneoplastic should be based on the presence or absence of cancer and the definitions of classical syndrome and well characterised onconeural antibody.

Abbreviations: LEMS, Lambert-Eaton myasthenic syndrome; PNS, paraneoplastic neurological syndrome; VGCC, voltage gated calcium channel.
Defining the cerebellar syndrome as classical, the following criteria are required: development in less than 12 weeks of a severe pancerbellar syndrome with no MR evidence of cerebellar atrophy other than that expected by the age of the patient. The severity of the cerebellar syndrome should cause a Rankin score of at least 3 (symptoms significantly interfere with lifestyle or prevent totally independent existence).

Predominant or isolated gait ataxia may be present in the first stage of the syndrome but clinical evidence of truncal and hemispheric cerebellar dysfunction is required for the diagnosis. The presence of symptoms or signs of involvement beyond the cerebellum is not uncommon and does not rule out the diagnosis. The coincidence with LEMS or positive P/Q type VGCC antibodies, present in around 40% of patients with paraneoplastic cerebellar degeneration and lung cancer, further supports the paraneoplastic origin of the cerebellar syndrome.

**Sensory neuronopathy**

The term neuronopathy is introduced to describe a neurological syndrome characterised by primary damage of the nerve cell body. The diagnosis of classical sensory neuronopathy should be considered if all the following criteria are present: subacute onset with a Rankin score of at least 3 before 12 weeks of evolution, onset of numbness, and often pain, marked asymmetry of symptoms at onset, involvement of the arms, proprioceptive loss in the areas affected, and electrophysiological studies that show marked, but not restricted, involvement of the sensory fibres with absent sensory nerve action potentials in at least one of the nerves studied.

Paraneoplastic sensory neuronopathy is not always an isolated syndrome and the neurological evaluation may
describe above are fulfilled, even if there is minor diagnosis of classical elicited by clinical or paraclinical examinations. Some patients present with sensory symptoms compatible with the definition of primary motor neuroneopathy, but also show severe motor weakness that may be caused by involvement of motorneurons in the anterior horn of the spinal cord or the peripheral nerves. These syndromes occur usually associated with SCLC and positive anti-Hu or CV2 antibodies. In this setting, if the clinical or electrophysiological examination recommend to use the term sensory neuroneopathy with motor involvement, rather than sensorimotor neuroneopathy that would imply a primary damage restricted to the peripheral nerve.

### Well characterised onconeural antibodies

Onconeural antibodies are found in patients with cancer and different types of PNS. There are several limitations that neurologists must be aware when using the onconeural antibodies in the diagnosis of PNS (table 2). Firstly, some antibodies have been described by a single group of investigators or reported in only a few patients. Secondly, although most onconeural antibodies described appear to be specific for PNS, a few patients never develop cancer after a follow up of several years.

The panel decided that, in the absence of a detected tumour, only well characterised onconeural antibodies (anti-Hu, Yo, CV2, Ri, Ma2, amphiphysin) should be used to classify the associated disorder as definite PNS. The term well characterised antibodies is based upon (1) antibodies for which there are recognisable patterns on routine immunohistochemistry and for which immunoblotting on recombinant proteins must be used to confirm their specificities; (2) the number of cases reported associated with tumours; (3) the description of well characterised neurological syndromes associated with the antibodies; (4) the unambiguous identification of the antibodies among different studies, and (5) the frequency of these antibodies in patients without cancer. Future studies will probably allow upgrading the

---

**Table 2 Onconeural antibodies**

<table>
<thead>
<tr>
<th>Antibody</th>
<th>No of patients reported</th>
<th>Identified by more than one laboratory</th>
<th>Paraneoplastic neurological syndrome</th>
<th>Tumours</th>
<th>% of antibody positive patients without cancer* (number of patients studied)</th>
<th>Frequency in cancer patients with PNS (number of patients studied)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Well characterised onconeural antibodies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-Hu (ANNA1)</td>
<td>&gt;600</td>
<td>Yes</td>
<td>Encephalomyelitis; sensory neuropathy; chronic gastrointestinal pseudo-obstruction; paraneoplastic cerebellar degeneration (PCD); limbic encephalitis</td>
<td>Small cell lung cancer (SCLC)</td>
<td>2% (200)†</td>
<td>16% (196 SCLC) (1% with titres similar to those patients with PNS)†</td>
</tr>
<tr>
<td>Anti-Yo (PCA1)</td>
<td>&gt;200</td>
<td>Yes</td>
<td>Paraneoplastic cerebellar degeneration</td>
<td>Ovary, breast</td>
<td>2% (125)†</td>
<td>1% (107)†</td>
</tr>
<tr>
<td>Anti-CV2 (CRMP5)</td>
<td>&gt;100</td>
<td>Yes</td>
<td>Encephalomyelitis; chorea; sensory neuropathy; sensorimotor neuropathy; chronic gastrointestinal pseudo-obstruction; paraneoplastic cerebellar degeneration; limbic encephalitis</td>
<td>SCLC, thymoma / C244</td>
<td>4% (47) †</td>
<td>9% (74 SCLC)‡</td>
</tr>
<tr>
<td>Anti-Ri (ANNA2)</td>
<td>61‡</td>
<td>Yes</td>
<td>Brainstem encephalitis</td>
<td>Breast, SCLC</td>
<td>3% (61)‡</td>
<td>4% (18) ovarian cancer†</td>
</tr>
<tr>
<td>Anti-Ma2 (Ta)</td>
<td>55‡</td>
<td>Yes</td>
<td>Limbic/diencephalic encephalitis; brainstem encephalitis/PCD</td>
<td>Testicular, lung</td>
<td>4% (55)‡</td>
<td>0% (350)†</td>
</tr>
<tr>
<td>Anti-amphiphysin</td>
<td>20‡</td>
<td>Yes</td>
<td>Stiff person syndrome; various syndromes</td>
<td>Breast SCLC</td>
<td>5% (20)‡</td>
<td>0% (25) gynaecological cancer† 1% (146 SCLC)†</td>
</tr>
</tbody>
</table>

**Partially characterised onconeural antibodies**

| Antibody               | No of patients reported | Identified by more than one laboratory | Paraneoplastic neurological syndrome                      | Tumours               | % of antibody positive patients without cancer* (number of patients studied) | Frequency in cancer patients with PNS (number of patients studied) |
|------------------------|-------------------------|---------------------------------------|                                                           |                       |                                                                                  |                                                                  |
| Anti-Tr (PCA-Tr)       | 28                      | Yes                                   | Paraneoplastic cerebellar degeneration                  | Hodgkin’s disease     | 11% (28)‡                                                                         | 0% (30)‡                                                        |
| ANNA3                  | 11                      | No                                    | Various syndromes                                       | SCLC                  | 9% (11)‡                                                                         | 0% (58)‡                                                        |
| PCA2                   | 9                       | No                                    | Various syndromes                                       | SCLC                  | 0% (8)†                                                                           | 2% (58)‡                                                        |
| Anti-Zic4              | 8                       | No                                    | Paraneoplastic cerebellar degeneration                  | SCLC                  | 12% (8)†                                                                          | 16% (74)†                                                        |
| Anti-mGlur1            | 2                       | No                                    | Paraneoplastic cerebellar degeneration                  | Hodgkin’s disease     | 50% (2)‡                                                                          | ?                                                                |

*Defined by number of patients with follow up of more than 3 years and no tumour found.
†Unpublished data from Dr J Honnorat.
‡Data collected from multiple case reports.
**Follow up of patients without cancer in reference 32 not specified.
*Data collected in part from unpublished data of Dr Dalmau and Dr Voltz. Patients with brainstem encephalitis/PCD usually associate with tumours different from testicular cancer and their sera also react against Ma1 protein.
**Follow up less than three years but antibody disappeared several months after the onset of the cerebellar syndrome.

---

**Table 3 Main clinical syndromes observed in encephalomyelitis**

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Pathological involvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Limbic encephalitis</td>
<td>Hippocampus, amygdala</td>
</tr>
<tr>
<td>Brainstem encephalitis (predominantly bulbar)</td>
<td>Medulla oblongata</td>
</tr>
<tr>
<td>Cerebellar degeneration</td>
<td>Purkinje cells</td>
</tr>
<tr>
<td>Myelitis (anterior horn)</td>
<td>Motor neurons</td>
</tr>
<tr>
<td>Sensory neuropathy</td>
<td>Dorsal root ganglia</td>
</tr>
<tr>
<td>Chronic gastrointestinal pseudo-obstruction</td>
<td>Myenteric plexus</td>
</tr>
</tbody>
</table>
partially characterised onconeural antibodies (anti-Tr, ANNA3, PCA2, Zic4, and mGluR1) to the group of well characterised antibodies. Other antineuronal antibodies occasionally detected in one or a few patients with PNS should not be used in the diagnosis of PNS until more data are obtained.

Diagnostic criteria for PNS

Based on these considerations, the panel suggested that there should be two levels of diagnostic evidence to define a neurological syndrome as paraneoplastic: “definite” and “possible”. Each level can be reached combining a set of criteria (table 4, fig 1). The panel recognises that the term “possible” may include true PNS but also the coincidental association of two unrelated disorders (the neurological syndrome and cancer). However, this level of evidence may be useful to identify disorders that in the future may be upgraded to definite PNS and to recognise PNS based on the identification of specific trends, such as a higher than expected association with a specific type of cancer. The panel emphasises that definite and possible PNS have in common the need to exclude other known causes that could explain the neurological syndrome under study even if onconeural antibodies are positive.

Criteria for definite PNS

1. A classical syndrome and cancer that develops within five years of the diagnosis of the neurological disorder

In this setting, the presence of onconeural antibodies is not required. A neurological syndrome will be diagnosed as classical if it is one of those underlined in table 1 and also fulfils the diagnostic criteria suggested in these recommendations. The time period of five years is based on previous work that shows that in patients with classical syndromes the tumour is almost always diagnosed within five years after the onset of the PNS.5 7 21

2. A non-classical syndrome that resolves or significantly improves after cancer treatment without concomitant immunotherapy, provided that the syndrome is not susceptible to spontaneous remission

The panel strongly recommends using objective measures to document the improvement of the clinical syndrome. The panel recognises that a stabilisation of the neurological syndrome may represent a response to tumour treatment with no further improvement noted due to irreversible neuronal damage. However, the neurological deficits of some syndromes may have reached a plateau or stabilise by the time the tumour is treated. This may lead to the impression that tumour treatment and stabilisation are related. The diagnosis of definite PNS should not apply to patients whose tumour treatment includes drugs that also are immunosuppressive and known to improve the associated neurological syndrome.

3. A non-classical syndrome with onconeural antibodies (well characterised or not) and cancer that develops within five years of the diagnosis of the neurological disorder

The inclusion in the definition of non-classical neurological syndromes may allow the identification of previously unrecognised PNS (such as chorea7) or upgrade as definite neurological syndromes that do not fulfil all the requirements.

---

**Table 4** Diagnostic criteria for paraneoplastic neurological syndromes (PNS)

<table>
<thead>
<tr>
<th>Definite PNS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. A classical syndrome and cancer that develops within five years of the</td>
</tr>
<tr>
<td>diagnosis of the neurological disorder</td>
</tr>
<tr>
<td>2. A non-classical syndrome that resolves or significantly improves after</td>
</tr>
<tr>
<td>cancer treatment without concomitant immunotherapy, provided that the</td>
</tr>
<tr>
<td>syndrome is not susceptible to spontaneous remission</td>
</tr>
<tr>
<td>3. A non-classical syndrome with onconeural antibodies (well characterised</td>
</tr>
<tr>
<td>or not) and cancer that develops within five years of the diagnosis of the</td>
</tr>
<tr>
<td>neurological disorder</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Possible PNS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. A classical syndrome, no onconeural antibodies, no cancer but at high</td>
</tr>
<tr>
<td>risk to have an underlying tumour</td>
</tr>
<tr>
<td>2. A neurological syndrome (classical or not) with partially characterised</td>
</tr>
<tr>
<td>onconeural antibodies and no cancer</td>
</tr>
<tr>
<td>3. A non-classical syndrome, no onconeural antibodies, and cancer present</td>
</tr>
<tr>
<td>within two years of diagnosis</td>
</tr>
</tbody>
</table>

---

**Figure 1** Flow chart showing the level of diagnostic evidence of the neurological syndrome according to the criteria defined by the panel.
to define them as classical (such as indolent sensory neuropathies) provided they are associated with onconeural antibodies.

4. A neurological syndrome (classical or not) with well characterised onconeural antibodies (anti-Hu, Yo, CV2, Ri, Ma2, or amphiphysin), and no cancer

The panel recognises that this set of criteria may include a very small number of false positive cases that will never develop cancer in spite of the presence of well characterised onconeural antibodies (table 2). A plausible explanation is that the tumour was eliminated by the immune response. Despite this limitation, the clinical data associated with these antibodies are robust enough to consider for practical purposes any patient who harbours well characterised onconeural antibodies as a carrier of a PNS and almost all reported patients have developed a cancer. By contrast, anti-Tr antibodies cannot be used to classify the PNS as definite in the absence of cancer because 11% (3/28) of patients reported never developed Hodgkin's disease and the antibody disappeared during the follow up.

Criteria for possible PNS

1. A classical syndrome, no onconeural antibodies, no cancer but at high risk to have an underlying tumour

Some classical syndromes are not associated with onconeural antibodies and may also occur in absence of cancer. The diagnosis of cancer during the follow up is the only way to define the syndrome as definite PNS. All these patients should have at least an initial work up for cancer. If cancer never develops after five years, the syndrome should be removed from the possible PNS category.

Presently, there are no clear clinical or biological markers that predict if the neurological syndrome, for example LEMS, is associated with cancer or not. However, there are some clues that may help neurologists to predict which patients with these classical syndromes are at high risk to have an underlying cancer (table 5). The panel’s recommendation is that the diagnosis of possible PNS, in the setting of the present set of criteria, should apply only to those classical syndromes that also have the identified risks for an underlying tumour.

2. A neurological syndrome (classical or not) with partially characterised onconeural antibodies and no cancer

Although the clinical information associated with partially characterised onconeural antibodies is limited, the present data suggest these onconeural antibodies are rarely seen in patients without cancer. Therefore, the neurological syndromes that fulfil the criteria defined above should be considered possible PNS until the follow up confirms or not the presence of an underlying tumour.

### Table 5: Clinical and biological clues that indicated an elevated risk of cancer in patients with classical syndromes and no onconeural antibodies

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Clues</th>
</tr>
</thead>
<tbody>
<tr>
<td>Limbic encephalitis</td>
<td>Negative VGKC antibodies and no recovery with immunotherapy</td>
</tr>
<tr>
<td>Subacute cerebellar degeneration</td>
<td>Positive VGCC antibodies or association with LEWMS</td>
</tr>
<tr>
<td>Opsoclonus-myoclonus syndrome</td>
<td>Age ≤ 5 or &gt; 40 years or no recovery with immunotherapy</td>
</tr>
<tr>
<td>Sensory neuropathy</td>
<td>Age &gt; 40 years and smoking habit</td>
</tr>
<tr>
<td>LEMS</td>
<td>Age &gt; 40 years and smoking habit</td>
</tr>
<tr>
<td>Dermatomyositis</td>
<td>Age &gt; 40 years</td>
</tr>
</tbody>
</table>

3. A non-classical neurological syndrome, no onconeural antibodies, and cancer present within two years of diagnosis

This definition probably will include neurological syndromes in which we cannot rule out a casual association with as common an event as cancer. To minimise false positive diagnosis of possible PNS, the panel decided to limit the time period between the neurological syndrome and the diagnosis of cancer to two years.

Although some cases of sensorimotor neuropathy were considered potential PNS early in the description of these syndromes, they are clinically and neurophysiologically heterogeneous and associated with different tumour types. This heterogeneity raises the possibility that at least in some situations, the coexistence of a neuropathy and cancer is coincidental. The recommendation of the panel is to define the neuropathy according to accepted criteria (that is, Guillain-Barré syndrome or chronic inflammatory demyelinating polyneuropathy) or to classify it as primary axonal or demyelinating, or prove the presence of microvasculitis. This approach may help to identify those neuropathies that more likely improve with immunotherapies, and to uncover or confirm specific associations between particular neuropathies and tumour types.

Final comments

Paraneoplastic neurological syndromes are rare disorders and even neurologists interested in the field personally examine only a few patients per year. The information collected from referring neurologists may miss detailed clinical or paraclinical information that may be important for a better definition of PNS. The present diagnostic criteria may help neurologists to report their patients with PNS more uniformly. The neuroimmunological research in PNS is a field in rapid evolution but at the same time with important limitations. For instance, the methodology to detect onconeural antibodies is not widely standardised, and with the discovery of new onconeural antibodies care must be taken to differentiate those that preferentially associate with PNS from those that may just reflect an antitumour immune response. Despite these limitations, the present recommendations on the diagnosis of PNS represent an attempt to clarify unresolved issues in this field. The future will prove if these recommendations have been useful to improve the diagnostic accuracy and research of PNS.

ACKNOWLEDGEMENTS

This study was supported by grant QLG1-CT-2002-01756 of the European Union.

OTHER MEMBERS OF THE PARANEOPLASTIC NEUROLOGICAL SYNDROME EURONETWORK

G Bertolino, Clinical Epidemiology laboratory, Instituto Mario Negri, Bergamo, Italy; A Carpenter, Service of Neurology, Hôpital de la Salpêtrière, Paris, France; I I Lorusso, Department of Neurology, Chiari (Brescia), Italy; I K Hart, Neuroimmunology Group, Department of Neurological Science, Liverpool, UK; J Pelota, Department of Pathology, Tampere, Finland; T Ros, Institute of Oncology, Medical Oncology/Neurology, Ljubljana, Slovenia; F Scaravilli, Division of Neuropathology, Institute of Neurology, UCL Queen Square, London, UK; P Stourac, Department of Neurology, Neuroimmunology Laboratory, Brno, Czech Republic; P A Tonali, Istituto di Neurologia, Università Cattolica Sacro Cuore, Rome, Italy; M C Vigliani, Department of Neurosciences, Torino, Italy.

---

Authors’ affiliations

F Graus, Service of Neurology, Institut d’Investigación Biomédica August Pi i Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain

J Y Delattre, Service of Neurology, Hôpital de la Salpêtrière, Unité INSERM 495, Paris, France
REFERENCES